Immunoblot analysis of phosphorylated estrogen receptor (ER)-α Ser118 and ER-α Ser167

Abstract

<p><b>Copyright information:</b></p><p>Taken from "Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer"</p><p>Breast Cancer Research 2005;7(5):R753-R764.</p><p>Published online 27 Jul 2005</p><p>PMCID:PMC1242143.</p><p>Copyright © 2005 Yamashita et al.; licensee BioMed Central Ltd.</p> Transfected COS-7 cells were grown in serum- and estrogen-deprived conditions and treated with vehicle (medium) (lane 1), 17β-estradiol (E) (lane 2), epidermal growth factor (EGF) (lane 3), or Eand EGF (lane 4) for 30 min. Equal amounts of total protein from whole cell lysates were blotted for either anti-ER-α-phosphoserine (α-pS118 and α-pS167) and anti-ER-α (α-ER-α) antibodies. T47D cells were grown in serum- and estrogen-deprived conditions and treated with vehicle (medium) (lane 1), 17β-estradiol (E) for 10 min (lane 2) and 30 min (lane 3), EGF for 10 min (lane 4) and 30 min (lane 5), or Eand EGF for 10 min (lane 6) and 30 min (lane 7). Equal amounts of total protein from whole cell lysates were blotted for either anti-ER-α-phosphoserine (α-pS118 and α-pS167) and anti-ER-α (α-ER-α) antibodies